GlassScriptPhysician profile
Brian S Crenshaw
NPI 1093778227
$2,977.92
in general payments reported to CMS, 2019-2025
29 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $131 · 2021: $401 · 2022: $483 · 2023: $785 · 2024: $411 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $723.46 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $517.87 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $321.15 | 2019-2023 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $176.64 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.46 | 2021-2024 | Jardiance |
| Pfizer INC. | $160.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $124.54 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.47 | 2019-2023 | Lifevest |
| Abiomed | $82.90 | 2023-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $71.56 | 2022-2023 | |
| Novo Nordisk INC | $59.37 | 2024-2025 | Wegovy, Ozempic |
| Irhythm Technologies, INC. | $50.95 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $49.33 | 2019-2024 | Farxiga, Brilinta |
| Heartflow, INC. | $44.74 | 2024 | |
| Abbott Laboratories | $43.14 | 2022-2023 | Cardiomems |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.27 | 2019 | |
| Daiichi Sankyo INC. | $37.16 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $32.94 | 2024 | Arcalyst |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Scpharmaceuticals INC. | $21.37 | 2025 | |
| Amarin Pharma, INC. | $18.67 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.62 | 2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $16.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.95 | 2022 | |
| Cook Medical LLC | $14.18 | 2021 | |
| Boston Scientific Corporation | $14.14 | 2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $13.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.19 | 2021 | |
| Cvrx, INC. | $10.10 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.